ANNOVERA
Peaksegesterone acetate and ethinyl estradiol
NDAVAGINALRING
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
6/8 — Strong
ANNOVERA (segesterone acetate and ethinyl estradiol) is estrogen receptor agonists [moa]. Approved for pregnancy. First approved in 2018.
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANNOVERA is a vaginal contraceptive ring combining segesterone acetate and ethinyl estradiol, approved in 2018 for pregnancy prevention. It functions as an estrogen receptor agonist, releasing hormones directly into systemic circulation to inhibit ovulation. The product targets women seeking long-acting reversible contraception with a non-daily administration burden.
$0.111MPart D
Peak13.1 years to LOEProduct is at peak commercial maturity with minimal Part D penetration, suggesting either a niche market positioning or significant untapped opportunity for field expansion.
Mechanism of Action
Estrogen Receptor Agonists
Pharmacologic Class:
Estrogen
Indications (1)
Career Relevance
ANNOVERA roles center on defensive market share protection and competitive differentiation rather than growth expansion; the small Part D footprint ($111K) and zero linked job postings suggest either a specialized niche product or an underinvested commercial opportunity. Career growth on this product is best suited for professionals seeking expertise in women's health contraceptives or those building market access skills in crowded therapeutic categories.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.